Revance Therapeutics, Inc.

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
2.71 ^USD	+1.50%		-10.26%	-69.17%

10/05	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
10/05	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Revance Therapeutics, Inc. Announce Resignation of Aubrey Rankin as A Member of the Board of Directors

March 25, 2022 at 01:34 am IST

On March 21, 2022, Aubrey Rankin provided notice of his resignation as a member of the Board of Directors of Revance Therapeutics, Inc. (the “Company”), effective as of the date of the Company's 2022 Annual Meeting of Stockholders. Mr. Rankin's decision is not a result of any disagreement on any matter relating to the Company's operations, policies or practices.

Latest news about Revance Therapeutics, Inc.

Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	10/05	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	10/05	MT
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	10/05	MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	10/05	CI
Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04/05	CI
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04/05	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	26/04	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12/04	CI
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM	12/03
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	11/03	DJ
Revance Therapeutics Prices $100 Million Public Offering	04/03	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	01/03	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	29/02	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	29/02	MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	29/02	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	29/02	CI
Revance Therapeutics, Inc. Announces Executive Changes	29/02	CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Revance Therapeutics Gets Permanent J-Code for Daxxify	02/02	DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02/02	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	02/02	RE
North American Morning Briefing : Microsoft Kicks -2-	30/01	DJ

Chart Revance Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Revance Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.71 USD

Average target price

13.5 USD

Spread / Average Target

+398.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REVANCE THERAPEUTICS, INC.	-69.17%	283M
CSL LIMITED	-2.00%	90.02B
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	39.15B
BIOGEN INC.	-15.83%	31.71B
UCB	+62.86%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.34B
INCYTE CORPORATION	-8.73%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	11.18B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	10.97B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.94B

Biopharmaceuticals